2020
The evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2018
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2018, 59: 217-225. PMID: 30427537, DOI: 10.1111/trf.15004.Peer-Reviewed Original ResearchConceptsPositive antibody screenDonor Evaluation Study-IIIAntibody screenRisk factorsRecipient EpidemiologyTransfusion historyBlood centersRBC alloantibodiesBlood donorsRed blood cell alloimmunizationCommon antibody specificitiesPrior transfusion historyRBC alloantibody formationSignificant RBC alloantibodiesHistory of transfusionAdjusted odds ratioMultivariable logistic regressionUS blood centersStudy IIIUS blood donorsPotent immune stimulusFuture medical careHealthy US blood donorsPrior transfusionsPrior pregnancy
2010
In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system
Snyder EL, Whitley P, Kingsbury T, Miripol J, Tormey CA. In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system. Transfusion 2010, 50: 2145-2151. PMID: 20497514, DOI: 10.1111/j.1537-2995.2010.02701.x.Peer-Reviewed Original ResearchConceptsRed blood cellsWhite blood cellsAutologous plateletsTransfusion productsBlood cellsAdverse clinical sequelaeCPD plasmaProduction of plateletsResidual white blood cellsClinical sequelaeDrug Administration requirementsHospital useVivo efficacyLeukoreduction filtersBlood centersStudy designVivo evaluationLR productsVivo characteristicsPlateletsRBC recoveryAdministration requirementsVitroSurvival ratioFDA guidelines